| Code | CSB-RA023986MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Denosumab-BBDZ, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates osteoclast differentiation, activation, and survival, playing a central role in bone remodeling and calcium metabolism. By binding to its receptor RANK on osteoclast precursors and mature osteoclasts, TNFSF11 promotes bone resorption. Dysregulation of the RANKL pathway is implicated in various skeletal disorders including osteoporosis, bone metastases, rheumatoid arthritis, and giant cell tumor of bone.
Denosumab-BBDZ is a fully humanized IgG2 monoclonal antibody that functions by binding to and neutralizing TNFSF11, thereby inhibiting osteoclast-mediated bone destruction. This biosimilar antibody serves as a valuable research tool for investigating bone metabolism, osteoclastogenesis, skeletal pathophysiology, and the RANK/RANKL/OPG signaling axis. It enables researchers to explore mechanisms underlying metabolic bone diseases and tumor-induced osteolysis in preclinical studies.
There are currently no reviews for this product.